
Big names from the government and life sciences, as well as top brass from Novartis (NOVN: VX), were in attendance as the Swiss pharma giant marked the official opening of its new UK headquarters.
Novartis has focused communications around the opening of the new site in White City, west London, on its launch of a new UK-centered clinical trial of the cardiovascular candidate inclisiran, which the company acquired in its $9.7 billion buy of The Medicines Company last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze